|
1
|
Macha MA, Seshacharyulu P, Krishn SR, Pai
P, Rachagani S, Jain M and Batra SK: MicroRNAs (miRNAs) as
biomarker(s) for prognosis and diagnosis of gastrointestinal (GI)
cancers. Curr Pharm Des. 20:5287–5297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ruepp A, Kowarsch A and Theis F: PhenomiR:
microRNAs in human diseases and biological processes. Methods Mol
Biol. 822:249–260. 2012. View Article : Google Scholar
|
|
4
|
Tüfekci KU, Meuwissen RL and Genç S: The
role of microRNAs in biological processes. Methods Mol Biol.
1107:15–31. 2014. View Article : Google Scholar
|
|
5
|
Tricoli JV and Jacobson JW: MicroRNA:
Potential for cancer detection, diagnosis, and prognosis. Cancer
Res. 67:4553–4555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dahiya N and Morin PJ: MicroRNAs in
ovarian carcinomas. Endocr Relat Cancer. 17:F77–F89. 2010.
View Article : Google Scholar :
|
|
7
|
Wyman SK, Parkin RK, Mitchell PS, Fritz
BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS and
Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as
determined by next generation sequencing of small RNA cDNA
libraries. PLoS One. 4:e53112009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thériault BL, Basavarajappa HD, Lim H,
Pajovic S, Gallie BL and Corson TW: Transcriptional and epigenetic
regulation of KIF14 overexpression in ovarian cancer. PLoS One.
9:e915402014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gschwind A, Fischer OM and Ullrich A: The
discovery of receptor tyrosine kinases: Targets for cancer therapy.
Nat Rev Cancer. 4:361–370. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S, Cui B, Lai H, Liu G, Ghia EM,
Widhopf GF II, Zhang Z, Wu CC, Chen L, Wu R, et al: Ovarian cancer
stem cells express ROR1, which can be targeted for
anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA.
111:17266–17271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y,
Tang X, Xu N, Zhang D, Xiong L, et al: ROR1 expression correlated
with poor clinical outcome in human ovarian cancer. Sci Rep.
4:58112014.PubMed/NCBI
|
|
12
|
Böcker W: WHO classification of breast
tumors and tumors of the female genital organs: Pathology and
genetics. Verh Dtsch Ges Pathol. 86:116–119. 2002.In German.
|
|
13
|
Kan CW, Howell VM, Hahn MA and Marsh DJ:
Genomic alterations as mediators of miRNA dysregulation in ovarian
cancer. Genes Chromosomes Cancer. 54:1–19. 2015. View Article : Google Scholar
|
|
14
|
Vargas-Hernández VM, Moreno-Eutimio MA,
Acosta-Altamirano G and Vargas-Aguilar VM: Management of recurrent
epithelial ovarian cancer. Gland Surg. 3:198–202. 2014.PubMed/NCBI
|
|
15
|
Goff BA, Mandel L, Muntz HG and Melancon
CH: Ovarian carcinoma diagnosis. Cancer. 89:2068–2075. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou XM, Zhang H and Han X: Role of
epithelial to mesenchymal transition proteins in gynecological
cancers: Pathological and therapeutic perspectives. Tumour Biol.
35:9523–9530. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang DH, Guo L and Wu XH: Checkpoint
inhibitors in immunotherapy of ovarian cancer. Tumour Biol.
36:33–39. 2015. View Article : Google Scholar
|
|
18
|
Muccioli M and Benencia F: Toll-like
Receptors in ovarian cancer as targets for immunotherapies. Front
Immunol. 5:3412014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garces AH, Dias MS, Paulino E, Ferreira CG
and de Melo AC: Treatment of ovarian cancer beyond chemotherapy:
Are we hitting the target? Cancer Chemother Pharmacol. 75:221–234.
2015. View Article : Google Scholar
|
|
20
|
Sethi S, Ali S, Sethi S and Sarkar FH:
MicroRNAs in personalized cancer therapy. Clin Genet. 86:68–73.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Casanova-Salas I, Rubio-Briones J,
Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A,
Rubio L, Ramírez-Backhaus M, Armiñán A, et al: Identification of
miR-187 and miR-182 as biomarkers of early diagnosis and prognosis
in patients with prostate cancer treated with radical
prostatectomy. J Urol. 192:252–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang C, Chen X, Alattar M, Wei J and Liu
H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis
of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li SQ, Chen FJ and Cao XF: Distinctive
microRNAs in esophageal tumor: Early diagnosis, prognosis judgment,
and tumor treatment. Dis Esophagus. 26:288–298. 2013. View Article : Google Scholar
|
|
24
|
Gounaris-Shannon S and Chevassut T: The
role of miRNA in haematological malignancy. Bone Marrow Res.
2013:2691072013. View Article : Google Scholar
|
|
25
|
Sethi S, Kong D, Land S, Dyson G, Sakr WA
and Sarkar FH: Comprehensive molecular oncogenomic profiling and
miRNA analysis of prostate cancer. Am J Transl Res. 5:200–211.
2013.PubMed/NCBI
|
|
26
|
Koutsaki M, Spandidos DA and Zaravinos A:
Epithelial-mesenchymal transition-associated miRNAs in ovarian
carcinoma, with highlight on the miR-200 family: Prognostic value
and prospective role in ovarian cancer therapeutics. Cancer Lett.
351:173–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takai M, Terai Y, Kawaguchi H, Ashihara K,
Fujiwara S, Tanaka T, Tsunetoh S, Tanaka Y, Sasaki H, Kanemura M,
et al: The EMT (epithelial-mesenchymal-transition)-related protein
expression indicates the metastatic status and prognosis in
patients with ovarian cancer. J Ovarian Res. 7:762014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu M, Jin H, Xu CX, Sun B, Song ZG, Bi WZ
and Wang Y: miR-382 inhibits osteosarcoma metastasis and relapse by
targeting Y box-binding protein 1. Mol Ther. 23:89–98. 2015.
View Article : Google Scholar
|
|
29
|
Cui B, Zhang S, Chen L, Yu J, Widhopf GF
II, Fecteau JF, Rassenti LZ and Kipps TJ: Targeting ROR1 inhibits
epithelial-mesenchymal transition and metastasis. Cancer Res.
73:3649–3660. 2013. View Article : Google Scholar : PubMed/NCBI
|
